Imsidolimab

BIOLOGICAL6 trials

Sponsors

Vanda Pharmaceuticals

Conditions

Acne VulgarisAcneiform EruptionsGeneralized Pustular PsoriasisHidradenitis SuppurativaIchthyosisPalmoplantar Pustulosis

Phase 2

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis

CompletedNCT03619902

Vanda PharmaceuticalsGeneralized Pustular Psoriasis

Start: 2019-01-30End: 2021-01-20Updated: 2025-09-16

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis

CompletedNCT03633396

Vanda PharmaceuticalsPalmoplantar Pustulosis

Start: 2019-05-20End: 2021-04-23Updated: 2025-09-15

A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Acneiform Rash

TerminatedNCT04697069

Vanda PharmaceuticalsAcneiform Eruptions

Start: 2021-05-04End: 2021-12-13Updated: 2025-09-22

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis

TerminatedNCT04697056

Vanda PharmaceuticalsIchthyosis

Start: 2021-01-25End: 2021-11-19Updated: 2025-09-16

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis Suppurativa

CompletedNCT04856930

Vanda PharmaceuticalsHidradenitis Suppurativa

Start: 2021-07-07End: 2022-12-14Updated: 2025-09-22

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris

CompletedNCT04856917

Vanda PharmaceuticalsAcne Vulgaris

Start: 2021-05-15End: 2022-03-29Updated: 2025-09-22

Related Papers

Efficacy and Safety of the Heat Shock Protein 90 Inhibitor RGRN-305 in Hidradenitis Suppurativa

JAMA Dermatology2023-12-0614 citations